Navigation Links
CryoCor Files Patent Infringement Lawsuits Against CryoCath
Date:1/16/2008

Seeks Injunction in the United States and Canada and Monetary Damages

SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it filed two patent infringement lawsuits against CryoCath Technologies Inc., one in the United States District Court for the District of Delaware and one in Canada.

The lawsuits allege that CryoCath's products infringe several patents related to CryoCor's Cardiac Cryoablation System. CryoCor is an exclusive licensee of the patents, and is seeking monetary damages and injunctions in the United States and Canada to prohibit further infringement.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "We believe that our exclusive license to these patents gives us broad coverage over key technologies that are critical in the field of cryoablation for cardiovascular applications. We have filed this lawsuit against CryoCath to enforce our intellectual property rights related to this critical segment of healthcare."

CryoCor has previously announced that it is pursuing patent interference proceedings initiated in 2004 with the United States Patent and Trademark Office. CryoCor's believes that it, through the licensor, was the first to invent certain pre-cooling technologies and is seeking that an interference be declared between CryoCath patents and CryoCor intellectual property to determine right of invention and ownership. CryoCor reported that it expects a patent interference proceeding to be declared by the U.S.P.T.O. in the first half of 2008.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the merits of CryoCor's positions in its litigation and interference proceedings with CryoCath and the possible outcome of that litigation and those interference proceedings, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward- looking statements.

Contact:

CryoCor, Inc. The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
2. CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. Arrow International Files and Mails Definitive Proxy Materials
8. VaxGen Files 2006 Financial Statements and Provides Cash Update
9. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
10. Anacor Files Registration Statement for Initial Public Offering
11. IsoTis Files Definitive Proxy Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Amawalk, NY (PRWEB) , ... January 16, 2017 ... ... for New Jersey laws precedential publication its decision on the appeal filed by ... FDASmart’s lawsuit of breach of contract against DPCL and one of its Dishman ...
(Date:1/14/2017)... ... January 14, 2017 , ... ... providing complete end-to-end genome assemblies to researchers around the globe. Long considered ... obstacle in answering a wide range of scientific questions. The announcement was ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... products containing an organic compound called fulvic acid that farms, greenhouses and hydroponics ... that grow cannabis are among the fastest growing segments of customers using this ...
(Date:1/12/2017)... , ... January 12, 2017 , ... Each year, Crain’s ... Index – a process that evaluates the patent estate of a company, its impact ... , a biomedical firm leading the way in technologies that transform energy sources such ...
Breaking Biology Technology:
(Date:1/4/2017)... Jan. 4, 2017  For the thousands of attendees at this year,s ... in connected health and biometric measurement devices and services, will be featuring ... On display in A&D Medical,s special CES Exhibit Suite , the ... expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
(Date:12/16/2016)... MIAMI , Dec. 16, 2016   ... intuitive Identity management products and solutions and a ... announced today that it is offering seamless, integrated ... Edam security entrance products. The solutions provide IdentyTech,s ... to secure their facilities from crime and theft. ...
Breaking Biology News(10 mins):